(R)-(2,3-dihydrobenzofuran-3-yl)methanol | 502435-02-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: (R)-(2,3-dihydrobenzofuran-3-yl)methanol
• 英文别名: (R)-1-(2,3-dihydro-benzofuran-3-yl)-methanol；[(3R)-2,3-dihydro-1-benzofuran-3-yl]methanol
• CAS: 502435-02-1
• 化学式: C₉H₁₀O₂
• 分子量: 150.177
• InChiKey: TYALRRRJZSULDN-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-(2,3-dihydrobenzofuran-3-yl)methanol 在 4-二甲氨基吡啶 、 caesium carbonate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Discovery of new orally active prostaglandin D2 receptor antagonists

  摘要：

  To identify an orally available drug candidate, a series of 3-benzoylaminophenylacetic acids were synthesized and evaluated as prostaglandin D-2 (PGD(2)) receptor antagonists. Some of the compounds tested were found to exhibit excellent inhibitory activity against cAMP accumulation in human platelet rich plasma (hPRP), which is one of the indexes of DP antagonism. The optimization process including improvement of the physicochemical properties such as solubility, which may result in an improved pharmacokinetic (PK) profile, is presented. Optimized compounds were studied for their pharmacokinetics and in vivo potential. A structure-activity relationship study is also presented. Some of the test compounds were found to have in vivo efficacy towards the inhibition of PGD(2)-induced and OVA-induced vascular permeability in guinea pig conjunctiva. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.08.065
• 作为产物：
  描述：

  (2S)-2-[(2-溴苯氧基)甲基]环氧乙烷 在 正丁基锂 、 盐酸 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 反应 2.0h， 以3.24 g的产率得到(R)-(2,3-dihydrobenzofuran-3-yl)methanol
  参考文献：
  名称：

  Discovery of selective indole-based prostaglandin D2 receptor antagonist

  摘要：

  A series of N-benzoyl-2-methylindole-3-acetic acids were synthesized and biologically evaluated as prostaglandin (PG) D-2 receptor antagonists. Some of the selected compounds significantly inhibited OVA-induced vascular permeability in guinea pig conjunctiva after oral dosing. Structure-activity relationship study is presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.06.014

文献信息

• Copper-Catalyzed Intramolecular Desymmetric Aryl CO Coupling for the Enantioselective Construction of Chiral Dihydrobenzofurans and Dihydrobenzopyrans
  作者：Wenqiang Yang、Yangyuan Liu、Shasha Zhang、Qian Cai

  DOI：10.1002/anie.201503882

  日期：2015.7.20

  O‐Heterocyclic structures such as 2,3‐dihydrobenzofurans are key motifs in many natural compounds and pharmaceuticals. Enantioselective formation of chiral dihydrobenzofurans and analogues was achieved through a copper‐catalyzed desymmetrization strategy with a chiral cyclic 1,2‐diamine. A broad range of substrates are compatible with this CuI‐diamine catalytic system and afford the desired coupling

  诸如2,3-二氢苯并呋喃之类的O杂环结构是许多天然化合物和药物中的关键基序。手性二氢苯并呋喃及其类似物的对映选择性形成是通过铜催化的手性环状1,2-二胺的去对称化策略实现的。各种各样的底物都可以与这种Cu I-二胺催化体系兼容，并在温和条件下以高收率和良好至优异的对映选择性提供具有手性叔或季碳中心的所需偶联产物。
• Enantioselective Synthesis of Chiral Oxygen-Containing Heterocycles Using Copper-Catalyzed Aryl C–O Coupling Reactions via Asymmetric Desymmetrization
  作者：Yong Zhang、Qiuyan Wang、Ting Wang、Huan He、Wenqiang Yang、Xinhao Zhang、Qian Cai

  DOI：10.1021/acs.joc.6b02646

  日期：2017.2.3

  An enantioselective desymmetric aryl C–O coupling reaction was demonstrated under the catalysis of CuI and a chiral cyclic diamine ligand. A series of chiral oxygen-containing heterocyclic units such as 2,3-dihydrobenzofurans, chromans, and 1,4-benzodioxanes with tertiary or quaternary stereocarbon centers were synthesized with this method. DFT calculations were also carried out for a better understanding

  在CuI和手性环二胺配体的催化下，对映选择性不对称芳基C-O偶联反应得到证实。用这种方法合成了一系列具有叔或季立体碳中心的手性含氧杂环单元，如2,3-二氢苯并呋喃，苯并二氢吡喃和1,4-苯并二恶烷。为了更好地理解对映控制模型，还进行了DFT计算。
• Indole derivatives, process for producing the same and drugs containing the same as the active ingredient
  申请人：Torisu Kazuhiko

  公开号：US20050004096A1

  公开（公告）日：2005-01-06

  Indole derivatives represented by formula (I) wherein all symbols represent the same as that in specification), production methods thereof, and DP receptor antagonist comprising them as active ingredients. Since the compounds of formula (I) binds and antagonizes to DP receptor, they are useful for the prevention and/or treatment against allergic diseases, diseases accompanied with itching, secondary diseases generated by behaviors caused by itching, inflammation, chronic obstructive pulmonary disease, ischemic reperfusion disorder, cerebrovascular disorder, pleuritis complicated by rheumatoid arthritis, ulcerative colitis.

  公式（I）所表示的吲哚衍生物（其中所有符号均与规范中相同），其生产方法以及包含它们作为活性成分的DP受体拮抗剂。由于公式（I）中的化合物结合并拮抗DP受体，因此它们对于预防和/或治疗过敏性疾病、伴随瘙痒的疾病、由瘙痒引起的行为所致的继发疾病、炎症、慢性阻塞性肺疾病、缺血再灌注障碍、脑血管疾病、风湿性关节炎并发的胸膜炎、溃疡性结肠炎等具有用处。
• ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES
  申请人：Hersperger Rene

  公开号：US20100016361A1

  公开（公告）日：2010-01-21

  A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: (I) wherein the variants R and X are defined in the specification.

  化合物公式（I）或其药学上可接受的盐或前药酯：（I），其中变异体R和X在规范中定义。
• Aryl carboxylic acid cyclohexyl amide derivatives
  申请人：Hersperger Rene

  公开号：US08354431B2

  公开（公告）日：2013-01-15

  A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: (I) wherein the variants R and X are defined in the specification.

  化合物公式（I）或其药学上可接受的盐或前药酯：（I）其中变异体R和X在规范中定义。